Tag Archives: Pascal Soriot

AstraZeneca's R&D Trimdown, Points to Shift in The Way Big Pharma Invents

AstraZeneca’s decision to cut 5,050 jobs by 2016 and cease R&D operations at its Alderley Park, UK facility has many wondering where CEO Pascal Soriot plans to take the company. The opening of a new $500 million facility in Cambridge is at once a consolation prize for the UK government’s efforts to placate a skittish […]
Posted in Biotech, Europe, R&D, Strategy | Also tagged , | Leave a comment
  • Categories

  • Meta